HIV/AIDS- Another disease of major concern is AIDS with a prevalence rate of 0.3%. Mexico is the second country in Latin America with highest reported cases of HIV. Anti-retroviral therapy is the most common therapy for AIDS. Lamivudine/zidovudine (COMBIVIR), zidovudine (AZT), ritonavir, indinavir, didanosine (ddI), lamivudine (3TC), zalcitabine (ddC), stavudine (d4T), nevirapine, saquinavir and efavirenz are the common drugs used for treatment of AIDS in Mexico.
Infections-Major infections in Mexico- Malaria, typhoid fever and dengue fever, and Meningitis.
Indian bulk drugs and finished formulations are exported to almost all the countries of Latin America .The Indian pharma companies have consolidated their presence in the region with a business of 400 million dollars. Some have established manufacturing units in Mexico and Brazil. Sensing the opportunity in Mexico, Indian and foreign generic producers have been expanding their presence here. Ranbaxy Laboratories and Wockhardt Limited have announced their Mexican joint venture plans, while in September 2005; Dr Reddy's Laboratories acquired Rochi's API (Active Pharmaceutical Ingredients) business in Mexico for $61.5 million.The leading pharmaceutical packaging company Bilcare from Pune is planning to start up a factory in Mexcico to tap the growing market. In 2005, Mexico sent an 11-member trade mission to India to explore ways in which to work with Indian pharmaceutical companies. As part of the visit, meetings were held with Ranbaxy Laboratories, Cipla Ltd, Biocon and Wockhardt. Elder Pharmaceuticals was the first Indian company to get a drug registered in Mexico. India’s leading generics player, Strides Acrolab Limited (Strides) has a manufacturing facility in Mexico.
India is emerging as a powerhouse of pharmaceutical R&D. The strength of the Indian Pharma industry lies in leveraging the country’s strengths in organic